title: Is pretreatment with ibutilide useful for atrial fibrillation cardioversion when combined with biphasic shock?
abstract: OBJECTIVE
  Cardioversion of atrial fibrillation by means of a monophasic transthoracic shock is facilitated by pretreatment with ibutilide. The aim of this study was to randomly and prospectively compare the energy requirements of transthoracic biphasic cardioversion of atrial fibrillation with and without ibutilide pretreatment.
  
  
  METHODS
  Fifty patients were enrolled and randomized into two groups: immediate cardioversion with biphasic shock (group 1) or ibutilide pretreatment followed by cardioversion with biphasic shock (group 2). In group 2, ibutilide was administered intravenously in 10 min at a dose of 0.01 mg/kg. A pause of 10 min was observed before the patients underwent cardioversion.
  
  
  RESULTS
  All patients of both groups were successfully cardioverted (100%). Energy and number of shocks were significantly lower in group 2 than in group 1 (P< 0.02). Eleven of 25 patients (44%) in group 1 and 15 of 23 patients (65%) in group 2 were cardioverted at the first attempt with 50 J. The number of patients cardioverted at the first attempt with 50 J was significantly higher in group 2 than in group 1 (P = 0.018).
  
  
  CONCLUSIONS
  Although not essential for a successful outcome, pretreatment with ibutilide can lower energy requirements in transthoracic biphasic cardioversion.
authors.affiliation: Cardiovascular Division-ICU, Azienda USL 6 of Livorno, Hospital of Cecina, Cecina (LI), Italy. jeanfrancis@interfree.it
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Mazzocca
authors.forename: Giorgio
authors.initials: G
authors.lastname: Corbucci
authors.forename: Elio
authors.initials: E
authors.lastname: Venturini
authors.forename: Lucia
authors.initials: L
authors.lastname: Becuzzi
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004554:Electric Countershock; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000889:Anti-Arrhythmia Agents; D013449:Sulfonamides; C067192:ibutilide